###
中国临床研究:2022,35(6):854-857
本文二维码信息
码上扫一扫!
TIGIT对血液淋巴系统恶性肿瘤的免疫调节作用
(兰州大学第二医院血液科,甘肃 兰州 730030)
Immunomodulatory effects of TIGIT on hematological malignancies
(Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China)
摘要
本文已被:浏览 377次   下载 245
投稿时间:2021-12-12   网络发布日期:2022-06-20
中文摘要: T细胞免疫球蛋白和免疫受体酪氨酸抑制性基序结构域 (TIGIT)是一种新的免疫检查点受体,是主要表达于T细胞和自然杀伤细胞(NK细胞)表面的一种免疫抑制性受体,通过抑制T细胞和NK细胞介导的免疫反应影响肿瘤微环境,促进肿瘤的发生发展。本文介绍TIGIT分子的结构与功能,并对TIGIT分子在血液淋巴系统恶性肿瘤的免疫调控、应用和前景作一综述。
Abstract:T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is a novel type of immune checkpoint receptor and an immunosuppressive receptor mainly expressed on the cell surface of T cells and NK cells. TIGIT affects the tumor microenvironment and promotes the occurrence and development of tumor by inhibiting the immune response mediated by T cells and NK cells. This paper introduces the structure and function of TIGIT molecule and reviews its immune regulation, application and prospect in hematological malignancies.
文章编号:     中图分类号:R733    文献标志码:A
基金项目:
引用文本:
王约拿,刘佳,李莉娟,张连生.TIGIT对血液淋巴系统恶性肿瘤的免疫调节作用[J].中国临床研究,2022,35(6):854-857.

用微信扫一扫

用微信扫一扫